Jagath R Junutula
Overview
Explore the profile of Jagath R Junutula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
2776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maecker H, Jonnalagadda V, Bhakta S, Jammalamadaka V, Junutula J
MAbs
. 2023 Aug;
15(1):2229101.
PMID: 37639687
The antibody-drug conjugate (ADC) field has undergone a renaissance, with substantial recent developmental investment and subsequent drug approvals over the past 6 y. In November 2022, Elahere became the latest...
2.
Suryamohan K, Diwanji D, Stawiski E, Gupta R, Miersch S, Liu J, et al.
Commun Biol
. 2021 Apr;
4(1):475.
PMID: 33846513
COVID-19 is a respiratory illness caused by a novel coronavirus called SARS-CoV-2. The viral spike (S) protein engages the human angiotensin-converting enzyme 2 (ACE2) receptor to invade host cells with...
3.
Bhakta S, Crocker L, Chen Y, Hazen M, Schutten M, Li D, et al.
Mol Cancer Ther
. 2019 Nov;
18(11):2182.
PMID: 31676543
No abstract available.
4.
Jiang Y, Liu B, Zheng Q, Panuganti S, Chen R, Zhu J, et al.
Blood Adv
. 2018 Jul;
2(14):1738-1749.
PMID: 30037800
The current standard of care for acute myeloid leukemia (AML) is largely ineffective with very high relapse rates and low survival rates, mostly due to the inability to eliminate a...
5.
Ohri R, Bhakta S, Fourie-ODonohue A, Dela Cruz-Chuh J, Tsai S, Cook R, et al.
Bioconjug Chem
. 2018 Feb;
29(2):473-485.
PMID: 29425028
THIOMAB antibody technology utilizes cysteine residues engineered onto an antibody to allow for site-specific conjugation. The technology has enabled the exploration of different attachment sites on the antibody in combination...
6.
Smith S, Jammalamadaka V, Borkin D, Zhu J, Degrado S, Lu J, et al.
ACS Med Chem Lett
. 2018 Jan;
9(1):56-60.
PMID: 29348812
Antibody-drug conjugates (ADCs) represent an important class of emerging cancer therapeutics. Recent ADC development efforts highlighted the use of pyrrolobenzodiazepine (PBD) dimer payload for the treatment of several cancers. We...
7.
Bhakta S, Crocker L, Chen Y, Hazen M, Schutten M, Li D, et al.
Mol Cancer Ther
. 2017 Dec;
17(3):638-649.
PMID: 29282299
Luminal A (hormone receptor-positive) breast cancer constitutes 70% of total breast cancer patients. In an attempt to develop a targeted therapeutic for this cancer indication, we have identified and characterized...
8.
Chaudhuri R, Khoo P, Tonks K, Junutula J, Kolumam G, Modrusan Z, et al.
NPJ Syst Biol Appl
. 2017 Jul;
1:15010.
PMID: 28725461
Objective: Insulin resistance (IR) is one of the earliest predictors of type 2 diabetes. However, diagnosis of IR is limited. High fat fed mouse models provide key insights into IR....
9.
Pillow T, Sadowsky J, Zhang D, Yu S, Rosario G, Xu K, et al.
Chem Sci
. 2017 Apr;
8(1):366-370.
PMID: 28451181
Disulfide bonds provide a bioactivatable connection with applications in imaging and therapy. The circulation stability and intracellular release of disulfides are problematically coupled in that increasing stability causes a corresponding...
10.
Pillow T, Schutten M, Yu S, Ohri R, Sadowsky J, Poon K, et al.
Mol Cancer Ther
. 2017 Feb;
16(5):871-878.
PMID: 28223423
A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody-drug conjugates (ADCs). ADCs...